Viatris Inc. (distributed by Meda Pharmaceuticals) is recalling 2,736 boxes of Levsin (hyoscyamine sulfate) injection. The recall was issued because the manufacturer discontinued a quality control program intended to ensure the drug meets standards for identity, strength, quality, and purity. This medication is used for various gastrointestinal and medical conditions, and this specific recall affects 0.5 mg per ml ampules in boxes of five. No incidents or injuries have been reported to date.
Because the quality control program was discontinued, the manufacturer cannot guarantee the injection contains the correct strength or purity of the active ingredient. Poor quality control in injectable medications can lead to ineffective treatment or potential contamination, though no specific adverse reactions have been reported.
You have 2 options:
Distributed by Meda Pharmaceuticals Inc. (a Viatris company).
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.